Evidence map›Paper›PMID 39588790›Full record

ArticleJournal of viral hepatitis2025

Challenges and Opportunities for Treating Hepatitis C Amongst People Who Use Drugs: Experience of an Integrated Mobile Clinic in Baltimore City.

Amanda Rosecrans, Robert Harris, Anne St Clair, Molly Rice, Meredith Zoltick, Catherine Willman, Anne King, Meredith Kerr, Kathleen R Page

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of viral hepatitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amanda RosecransDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0003-3230-0684
Robert HarrisDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Anne St ClairDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Molly RiceDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Meredith ZoltickInstitute of Human Virology at the University of Maryland School of Medicine, Baltimore, Maryland, USA.
Catherine WillmanDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Anne KingDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Meredith KerrJohns Hopkins School of Nursing, Baltimore, Maryland, USA.
Kathleen R PageDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Funding

Mentoring in Community-engaged Research to Promote Outcomes for LatinosK24NR020508 · NINR · JOHNS HOPKINS UNIVERSITY · PI Kathleen R Page · 2022 to 2026
$942k
CDC HHSNINR NIH HHS K24 NR020508SAMHSA HHS
6 · The paper itself

Abstract

Progress in treating chronic hepatitis C virus (HCV) infection has been slow amongst people who use drugs (PWUD). This study describes the HCV treatment cascade amongst people accessing a mobile clinic offering integrated low-threshold buprenorphine and infectious disease services in Baltimore City. From May 1, 2021, to December 31, 2022, 560 people had a rapid HCV antibody test, of whom 201 (36%) had a positive result and amongst those, 117 (58%) had an HCV RNA test performed, 81 (40%) had a documented positive RNA, 45 (22%) were prescribed medication, 42 (21%) started medication, 32 (16%) completed medication, 22 (11%) had blood work to assess for sustained virologic response and 20 (10%) had a documented cure. Challenges including housing instability, insurance barriers and lack of venous access limit progress in this cascade. Providing integrated care models to meet the needs of PWUD in the community is necessary but not sufficient to make progress in improving HCV treatment. Removal of insurance restrictions, availability of point-of-care HCV RNA testing, development of rapid HCV treatment guidelines and development of long-acting injectable HCV treatment are needed to move towards a same-day, one-time test and treat model of care.

Indexed as

Antiviral AgentsDrug UsersHepatitis C, ChronicMobile Health UnitsSubstance Abuse, IntravenousAdultBaltimoreFemaleHepacivirusHumansMaleMiddle AgedRNA, ViralSustained Virologic ResponseAntiviral AgentsRNA, Viralhepatitis C treatmenthomelessmobile clinicpeople who use drugs

Identifiers

PMID39588790
PMCPMC13249361

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.